Response to the Upcoming Emerging Waste: Necessity and Feasibility Analysis of Photovoltaic Waste Recovery in China.

With the widespread photovoltaic deployment to achieve the net-zero energy goal, the resulting photovoltaic waste draws attention. In China, considerable steps have not been taken for photovoltaic waste management. The lack of relevant scientific information on photovoltaic waste brings difficulties to the establishment of photovoltaic waste regulatory systems. In this study, the necessity and feasibility of photovoltaic waste recovery were investigated. In China, the photovoltaic waste stream was quantified as 48.67-60.78 million t in 2050. In photovoltaic waste, indium, selenium, cadmium, and gallium were in high risk, judging by the metal criticality analysis, which meant that their recovery was significant to alleviate the resource shortage. The full recovery method was proved to reduce the environmental burdens most. For cost and benefit analysis, the net present value/size was -1.02 $/kg according to the current industrial status. However, it can be profitable with the recovery of silver. This study provides scientific and comprehensive information for photovoltaic waste management in China and is expected to promote the sustainable development of photovoltaic industry.

[Critical coronavirus disease 2019 complicated with heparin resistance in 2 patients].

OBJECTIVE: To explore the diagnosis process and treatment experience of severe coronavirus disease 2019 (COVID-19) patients with heparin resistance (HR). METHODS: The medical team of the First People's Hospital of Lianyungang admitted 2 severe COVID-19 patients with HR in intensive care unit (ICU) during their support to the designated hospital for the treatment of COVID-19 patients in Lianyungang City in November 2021. The clinical features, laboratory examinations, imaging features, treatment and prognosis of the two patients were analyzed. RESULTS: Both severe COVID-19 patients received mechanical ventilation, 1 patient was treated with extracorporeal membrane oxygenation (ECMO) support. Both patients were complicated with lower extremity deep venous thrombosis and HR phenomenon under routine dose anticoagulant therapy. The maximum daily dose of unfractionated heparin exceeded 35 000 U (up to 43 200 U), the 2 patients failed to meet the standard of anticoagulation treatment, and the course of disease was prolonged. After that, argatroban was given 0.4 µg×kg-1×min-1 combined with anticoagulant therapy, the activated partial thromboplastin time (APTT) of patients undergoing ECMO could be maintained at 55-60 seconds and the activated coagulation time (ACT) of them could be maintained at 180-200 seconds. After ECMO support or later sequential mechanical ventilation, both patients recovered and were discharged, and deep venous thrombosis was also effectively controlled. CONCLUSIONS: HR phenomenon often occurs during the treatment of severe COVID-19 patients, the anticoagulation regimen should be adjusted in time, and the anticoagulation effect combined with argatroban is clear.